When it comes to treating chronic wounds, advanced wound care technologies have come a long way. However, diabetic foot ulcers (DFUs) can be complicated to treat, and not every patient should receive the same course of treatment. Patient-centered care is a far more effective strategy than traditional approaches. Understanding the particular needs of each patient and the pathophysiology of diabetic wound chronicity are critical factors in the management of diabetic foot ulcers (DFUs). Ideally, the primary goal should be wound closure, with secondary goals being the prevention of recurrence. We must incorporate ongoing education and clinical support into our efforts to achieve both objectives. Healthcare practitioners should stay updated on the most recent evidence-based research and practices to provide their patients with the most personalized advanced therapy possible.
Methods for Offloading
Offloading is essential when it comes to the closure of diabetic foot ulcers. Pain responses are inhibited in diabetics with neuropathy. Because of the number of load cycles per day that cause more tissue damage, reducing shear and pressure tissue forces is crucial in aiding healing. A wheelchair, crutches, and walkers are examples of offloading devices. There are several different treatment techniques available for offloading therapy, such as therapeutic shoes, custom insoles, post-op shoes and or sandals, pad and protect dressings, removable cast boots (RCB), and total contact casts (TCC).
Wound Bed Preparation
The wound cleansing technique should be carried out with the use of a noncytotoxic solution in wound bed preparation. In chronic wounds, bacterial balance is achieved by applying topical antimicrobial and antibacterial agents. This lowers the number of bacteria present. Bioburden, also known as biofilm, is a substance that interferes with healing and increases the risk of infection.
The use of one or more of the five methods of debridement is critical in the formation of an appropriate wound bed. A healthy wound bed promotes the ability for healing to take place in the wound. It is possible to use many debridement treatments at the same time to achieve the best possible healing results. Biologic, enzymatic, autolytic, mechanical, and surgical means of debridement are available to specialists. To advance wound chronicity along a trajectory toward closure, the debridement treatments discussed above remove dead, damaged, or contaminated tissue.
Collagen Advanced Wound Care Dressings
In addition to bovine and porcine collagen dressings, there are also horse, ovine, Piscean, and avian collagen dressings available. In accordance with the manufacturer, collagen-based dressings are available in particle, pad, gel, solution, or paste form. A prolonged inflammatory response and abnormality of the extracellular matrix (ECM) have been observed in DFUs. I Collagen dressing technologies provide support and help to build a scaffolding matrix that regulates extracellular components, allowing chronic wounds to heal more quickly and effectively.
With appropriate blood flow, becaplermin 0.01 percent is the only FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) for the treatment of full thickness lower extremity diabetic ulcers. In addition to stimulating and supporting the wound healing process, this topical agent Clinical trial data confirmed that Becaplermin can help lower the risk of amputation and that one-third more DFUs healed in the active group with daily rhPDGF-BB compared to the placebo control group at week 20 when compared to the placebo group. According to the research, becaplermin is 43 percent more likely than placebo gel to improve the healing of neuropathic ulcers.
Cellular and Tissue-Based Products (CTPs)
Among the FDA-approved products for the evidence-based treatment of diabetic foot ulcers are placental/amnionic/chorionic derived products generated from placental/amniotic/chorionic tissue (DFUs). When compared to generic wound care standards, there is evidence to imply a lower risk of amputation and a higher rate of wound closure. Different skin cells, such as fibroblasts and keratinocytes, are provided via tissue-based products or skin replacements to aid in tissue regeneration. Extracellular matrix for tissue growth is created by bioengineered products, which can be made of natural or synthetic materials.
The discomfort, complexity, and expense associated with diabetic foot ulcers can be significant for both the patient and the healthcare provider. If diabetic foot ulcers are not prevented, recognized early, adequately controlled, and treated as needed, complications might occur, resulting in infection, amputation, and even death if they are not treated appropriately. Depending on clinical findings, specific treatment planning, and insurance coverage, advanced wound care technology should be used. Monitoring and re-evaluation of vascular status, offloading, compliance, and medical care are essential to achieving the healing goals of DFUs patients.
The views and opinions stated in this blog are exclusively those of the author and do not reflect those of iWound, its affiliates, or partner companies.